[HTML][HTML] New targeted therapies in pancreatic cancer

A Seicean, L Petrusel, R Seicean - World journal of …, 2015 - ncbi.nlm.nih.gov
Patients with pancreatic cancer have a poor prognosis with a median survival of 4-6 mo and
a 5-year survival of less than 5%. Despite therapy with gemcitabine, patient survival does …

[PDF][PDF] New targeted therapies in pancreatic cancer

A Seicean, L Petrusel, R Seicean - World J Gastroenterol, 2015 - researchgate.net
Patients with pancreatic cancer have a poor prognosis with a median survival of 4-6 mo and
a 5-year survival of less than 5%. Despite therapy with gemcitabine, patient survival does …

New targeted therapies in pancreatic cancer

A Seicean, L Petrusel… - World journal of …, 2015 - pubmed.ncbi.nlm.nih.gov
Patients with pancreatic cancer have a poor prognosis with a median survival of 4-6 mo and
a 5-year survival of less than 5%. Despite therapy with gemcitabine, patient survival does …

New targeted therapies in pancreatic cancer.

A Seicean, L Petrusel, R Seicean - World Journal of …, 2015 - europepmc.org
Patients with pancreatic cancer have a poor prognosis with a median survival of 4-6 mo and
a 5-year survival of less than 5%. Despite therapy with gemcitabine, patient survival does …

[HTML][HTML] New targeted therapies in pancreatic cancer

A Seicean, L Petrusel, R Seicean - World Journal of Gastroenterology, 2015 - wjgnet.com
Patients with pancreatic cancer have a poor prognosis with a median survival of 4-6 mo and
a 5-year survival of less than 5%. Despite therapy with gemcitabine, patient survival does …

[引用][C] New targeted therapies in pancreatic cancer

A Seicean, L Petrusel, R Seicean - World Journal of Gastroenterology, 2015 - wjgnet.com
New targeted therapies in pancreatic cancer Home English English 简体中文 Sign In BPG
Management System F6Publishing-Submit a Manuscript F6Publishing-世界华人消化杂志在线 …